Again Acquires Genomatica: Combining AI-Driven Discovery with Industrial Biomanufacturing

On August 12, 2026, Denmark-based Again (LuaBio ApS) announced the acquisition of Genomatica Inc., widely known as Geno, the San Diego-based pioneer in industrial bioprocess engineering . The deal fuses Again's biomanufacturing scale-up capabilities with Geno's AI-driven discovery and design platform for biomolecules, creating an end-to-end engine from molecule design to commercial production . Financial terms were not disclosed .

Strategic Rationale: Why Again Bought Geno

Data is the core asset. Again told multiple outlets that the deal is fundamentally about acquiring Geno's AI computational biotech platform and patent portfolio, which includes decades of experimental results, structural data, scale-up insights, and development outcomes . More data sharpens Again's computational models and compresses the timeline from molecule discovery to market .

End-to-end capability. The two companies previously operated on different sides of biomanufacturing. Again focused on CO₂-to-chemical fermentation at scale via modular bioreactors co-located with industrial emitters, using engineered Moorella bacteria. Geno specialized in sugar-based fermentation using engineered E. coli and AI-guided pathway design. The merger creates what the companies describe as an "AI design-to-scale" engine .

Geopolitical timing. The acquisition arrives amid reshoring tailwinds from the U.S. BIOSECURE Act and the EU's Biotech Act II, policies expected to mobilize tens of billions of dollars in domestic bio-based supply chains .

Existing ties. Geno co-founder Christophe Schilling already sat on Again's board of directors, indicating a pre-existing strategic relationship .

Capabilities Combined

Again	Genomatica (Geno)
Modular bioreactors co-located with industrial CO₂ emitters	AI and computational platform for de novo molecule discovery and design
Engineered Moorella bacteria converting CO₂ + H₂ into acetate, acetic acid, and derivatives	Engineered E. coli strains fermenting plant sugars into chemicals
AI-driven bioprocess design suite and scale-up modeling	20+ years of in silico pathway/strain design and ML analytics
Commercial-scale acetic acid plant in Texas (since 2025)	Licensed commercial processes for BDO, nylon precursors, palm oil alternatives
Operations in Copenhagen, Munich, and Houston	Partnerships with Novamont, Qore (Cargill/Helm), Unilever, Kao, Aquafil

Combined emissions impact: The companies estimate that the combined platform can divert up to 85 million tons of CO₂ per year through direct capture and avoided emissions . This figure mixes direct capture with avoided emissions and is based on the companies' own estimates.

The acquisition also gives Again access to Geno's intellectual property, computational models, and decades of process development data . Again says the purchase will help it expand into other renewable feedstocks, including sugars .

Financial Terms: Undisclosed

Neither company revealed the purchase price or deal structure . For context, Again had raised $67 million since its 2021 founding, per PitchBook .

Future Commercial Model: License, Co-Develop, and Sell

The combined company will operate a diversified, three-pronged commercial approach :

1. Licensing technology where it scales, continuing Geno's model of licensing processes to manufacturers like Novamont and Qore.
2. Co-developing production pathways where they are mission-critical for partners.
3. Selling products from existing and upcoming assets, including Again's own production facilities.

This model is designed to "capture value at every stage" of the biomanufacturing value chain .

CEO Statement

Max Kufner, CEO of Again, said:
"AI is revolutionizing biology, but algorithms are only as good as their ability to translate into real-world, commercial-scale execution. Geno pioneered AI and computational biotechnology for molecule discovery and design. By integrating that with our scale-up platform and novel feedstock technologies, we are building the world's leading biomanufacturing platform, unlocking novel products and supply-chains that industries critically need."

Key Caveats

• Financial terms remain undisclosed .
• The emissions figure of 85 million tons CO₂/year is based on the companies' own estimates and mixes direct capture with "avoided emissions" .
• All existing Geno partners "will continue to be supported throughout the transition" .